Maravai LifeSciences Q2 revenue beats estimates on strong TriLink demand
MRVI•Outlook for 2026
- Maravai sees 2026 revenue between $205 mln and $215 mln.
- Company raises 2026 adjusted EBITDA guidance to $33 mln-$35 mln from $30 mln-$32 mln.
- Company expects continued demand for TriLink and Cygnus products to support growth.
Quarterly results beat estimates
- Life science reagents supplier's Q2 revenue rose 9% yr/yr, beating analyst expectations.
- Q2 adjusted EBITDA beat analyst expectations, driven by TriLink segment demand.
- Company raised full-year 2026 adjusted EBITDA guidance, maintained revenue outlook.
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Beat | $51.40 mln | $48.68 mln (8 Analysts) |
| Q2 Net Loss | $21.60 mln | ||
| Q2 Adjusted EBITDA | Beat | $8.70 mln | $3.05 mln (8 Analysts) |
Result drivers and analyst coverage
- TriLink demand - TriLink revenue rose 11.5% yr/yr, driven by higher demand for research-use raw materials and GMP consumables used in clinical trials.
- - Cygnus revenue grew 2.8% yr/yr, supported by demand for Host Cell Protein and ELISA kits and strength in China due to distributor ordering timing.
